Deliberazione - 583 - 21/11/2024

Emendamento all’accordo stipulato tra Theravance Biopharma Ireland Limited e l’ASST Gaetano Pini-CTO, relativa allo studio “A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy” - Codice Protocollo CYPRESS STUDY